

# Peter R Bieck

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6051055/publications.pdf>

Version: 2024-02-01

17  
papers

446  
citations

840776

11  
h-index

888059

17  
g-index

20  
all docs

20  
docs citations

20  
times ranked

272  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | Exploratory Biomarker Study of the Triple Reuptake Inhibitor SEP432 Compared to the Dual Reuptake Inhibitor Duloxetine in Healthy Normal Subjects. <i>CNS Neuroscience and Therapeutics</i> , 2016, 22, 404-412. | 3.9 | 2         |
| 2  | Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 675-683.   | 1.4 | 7         |
| 3  | BIOMARKERS IN PSYCHOTROPIC DRUG DEVELOPMENT: Integration of Data across Multiple Domains. <i>Annual Review of Pharmacology and Toxicology</i> , 2005, 45, 227-246.   | 9.4 | 29        |
| 4  | Clinical Assessment of Norepinephrine Transporter Blockade Through Biochemical and Pharmacological Profiles. <i>Circulation</i> , 2004, 109, 3202-3207.  | 1.6 | 92        |
| 5  | Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study. <i>Neuropsychopharmacology</i> , 2003, 28, 1685-1693.                                      | 5.4 | 85        |
| 6  | The Tyramine Pressor Test May Have Limited Sensitivity, Especially in the Presence of Dual Serotonin/Norepinephrine Uptake Inhibition. <i>Neuropsychopharmacology</i> , 2002, 26, 698-699.                       | 5.4 | 13        |
| 7  | Clinical pharmacology of the new COMT inhibitor CGP 28 014. <i>Neurochemical Research</i> , 1993, 18, 1163-1167.   | 3.3 | 11        |
| 8  | The $\alpha$ -serotonin/norepinephrine link™ beyond the $\beta^2$ adrenoceptor. <i>Molecular Brain Research</i> , 1992, 16, 211-214.   | 2.3 | 17        |
| 9  | Dose-dependent down-regulation of $\alpha$ -adrenoceptors by isoproterenol in rat C6 glioma cells. <i>European Journal of Pharmacology</i> , 1992, 225, 171-174.   | 2.6 | 5         |
| 10 | Tyramine kinetics and pressor sensitivity during monoamine oxidase inhibition by selegiline. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 46, 528-536.  | 4.7 | 62        |
| 11 | Monoamine oxidase inhibition by phenelzine and brofaromine in healthy volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 260-269.   | 4.7 | 38        |
| 12 | Effect of brofaromine and pargyline on human plasma melatonin concentrations. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1988, 12, 93-101.  | 4.8 | 20        |
| 13 | Interaction of Alcohol and Transdermally Administered Scopolamine. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 1123-1127.  | 2.0 | 1         |
| 14 | Metabolic fate of CGS 8216, a benzodiazepine receptor antagonist, in rat and in man. <i>Psychopharmacology</i> , 1986, 88, 529-30.   | 3.1 | 9         |
| 15 | Transdermally applied scopolamine does not impair psychomotor performance. <i>Psychopharmacology</i> , 1984, 83, 397-398.  | 3.1 | 8         |
| 16 | Antilipolytic effect of N6, 2'-O-dibutyl-3',5'-adenosine monophosphate in vivo. <i>Life Sciences</i> , 1968, 7, 1125-1134.   | 4.3 | 15        |
| 17 | Lipolytic action of serotonin. <i>Life Sciences</i> , 1966, 5, 2157-2163.  | 4.3 | 24        |